Advances in the Immunogenic Design of HIV-1 Vaccine / 病毒学报
Chinese Journal of Virology
;
(6): 88-92, 2016.
Article
Dans Chinois
| WPRIM
| ID: wpr-296212
ABSTRACT
A safe and effective vaccine against the human immunodeficiency virus type 1 (HIV-1) is expected to have a considerable impact on elimination of acquired immune deficiency syndrome. Despite decades of effort, an effective vaccine against HIV-1 remains elusive. In recent years, the Thai HIV Vaccine Efficacy Trial (known as RV144) showed a reduction in HIV-1 acquisition by 31%, but this agent could not delay disease progression in vaccinated individuals. Clinical analyses of experimental data and experiments in vitro have revealed two main types of immunogen design:
induction of broad-spectrum neutralizing antibody (bNAb) and cytotoxic T lymphocyte (CTL) responses. bNAb can prevent or reduce acquisition of infection, and its main immunogens are virus-like particles, natural envelope trimers and stable bNAb epitopes. An effective CTL response can slow-down viral infection, and its main immunogens are "mosaic" vaccines, "conserved immunogens", and the "fitness landscape" of HIV-1 proteins. This review summarizes the strategies as well as progress in the design and testing of HIV-1 immunogens to elicit bNAb and CTL responses.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Virologie
/
Conception de médicament
/
Anticorps anti-VIH
/
Infections à VIH
/
VIH-1 (Virus de l'Immunodéficience Humaine de type 1)
/
Vaccins contre le SIDA
/
Allergie et immunologie
/
Génétique
Limites du sujet:
Animaux
/
Humains
langue:
Chinois
Texte intégral:
Chinese Journal of Virology
Année:
2016
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS